Development of MAIR-I (CD300a) as a molecular target of sepsis treatment
| Project/Area Number |
23592664
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | MAIR-I / 敗血症 / アポトーシス細胞 / フォスファチジルセリン / 肥満細胞 / サイトカイン / CD300a / アポトーシス / リガンド |
|---|
| Research Abstract |
We identified that the immunoreceptor MAIR-I (CD300a), which is expressed on myeloid cells including mast cells, is a phosphatidylserine (PS) receptor. We showed that MAIR-I does not facilitate macrophage phagocytosis of apoptotic cells, but rather inhibits the production of inflammatory cytokines and chemokines from mast cells that to recruit neutrophils to the peritoneal cavity to clear bacteria during murine sepsis model. We showed MAIR-I on mast cells and PS binding contributes to the survival of murine sepsis model.
|
Report
(4 results)
Research Products
(50 results)
-
-
-
-
-
-
-
-
-
[Journal Article] Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor.2012
Author(s)
Nakahashi-Oda, C., Tahara-Hanaoka, S., Shoji, M., Okoshi, Y., Nakano-Yokomizo, T., Ohkohchi, N., Yasui, T., Kikutani, H., Honda, S., Shibuya, K., Nagata, S. and Shibuya, A.
-
Journal Title
J Exp. Med.
Volume: 209
Issue: 8
Pages: 1493-1503
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
